Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedJun 01, 2026
DataAggregated Company Financials
Companies7
  • 7D1.3%
  • 3M0.2%
  • 1Y-6.5%
  • YTD-0.2%

In the last week, the Life Sciences industry is up 1.3%, with Lonza Group up 0.7%. During this same period, the Bachem Holding underperformed, falling 7.6%. However, the industry is down 6.5% over the past year. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 03 Jun 2026CHF 48.7bCHF 10.1bCHF 1.1b38.6x44.7x4.8x
Fri, 01 May 2026CHF 46.1bCHF 10.1bCHF 1.1b35.7x40.3x4.6x
Sun, 29 Mar 2026CHF 46.0bCHF 10.1bCHF 1.1b31.7x40.2x4.5x
Tue, 24 Feb 2026CHF 48.0bCHF 10.1bCHF 1.3b29.1x37.2x4.7x
Thu, 22 Jan 2026CHF 52.5bCHF 10.6bCHF 1.1b33.9x47.8x4.9x
Sat, 20 Dec 2025CHF 48.6bCHF 10.6bCHF 1.1b28.7x44.2x4.6x
Mon, 17 Nov 2025CHF 49.1bCHF 10.6bCHF 1.1b28.3x44.6x4.6x
Wed, 15 Oct 2025CHF 48.2bCHF 10.6bCHF 1.1b29.6x43.9x4.5x
Fri, 12 Sep 2025CHF 51.9bCHF 10.6bCHF 1.1b32.9x47.1x4.9x
Sun, 10 Aug 2025CHF 51.6bCHF 10.7bCHF 1.1b33.4x44.9x4.8x
Tue, 08 Jul 2025CHF 52.0bCHF 10.1bCHF 1.0b32.7x50x5.2x
Thu, 05 Jun 2025CHF 52.1bCHF 10.1bCHF 1.0b30.8x50.1x5.2x
Sat, 03 May 2025CHF 55.0bCHF 10.1bCHF 1.0b31.5x52.9x5.5x
Mon, 31 Mar 2025CHF 53.1bCHF 10.1bCHF 1.0b33.1x51.8x5.3x
Wed, 26 Feb 2025CHF 55.4bCHF 10.1bCHF 1.0b32.5x53.4x5.5x
Fri, 24 Jan 2025CHF 56.5bCHF 10.2bCHF 943.2m35.9x59.9x5.5x
Sun, 22 Dec 2024CHF 52.2bCHF 10.2bCHF 943.6m35.2x55.3x5.1x
Tue, 19 Nov 2024CHF 51.8bCHF 10.2bCHF 943.5m40.9x54.9x5.1x
Thu, 17 Oct 2024CHF 54.4bCHF 10.2bCHF 943.4m41.3x57.7x5.3x
Sat, 14 Sep 2024CHF 57.5bCHF 10.2bCHF 937.0m44.5x61.3x5.6x
Mon, 12 Aug 2024CHF 57.4bCHF 10.2bCHF 924.0m45.2x62.2x5.6x
Wed, 10 Jul 2024CHF 54.0bCHF 10.3bCHF 1.0b46.6x53.9x5.3x
Fri, 07 Jun 2024CHF 53.6bCHF 10.3bCHF 1.0b43.9x53.5x5.2x
Sun, 05 May 2024CHF 54.4bCHF 10.3bCHF 1.0b43.4x54.3x5.3x
Tue, 02 Apr 2024CHF 58.5bCHF 10.3bCHF 1.0b47x58.3x5.7x
Thu, 29 Feb 2024CHF 50.6bCHF 10.2bCHF 982.4m46.9x51.6x5x
Sat, 27 Jan 2024CHF 46.5bCHF 10.2bCHF 1.0b42.3x45.6x4.6x
Mon, 25 Dec 2023CHF 41.8bCHF 9.8bCHF 1.5b32.4x28x4.3x
Wed, 22 Nov 2023CHF 41.3bCHF 9.8bCHF 1.5b29.5x27.7x4.2x
Fri, 20 Oct 2023CHF 39.1bCHF 9.8bCHF 1.5b27.2x26.2x4x
Sun, 17 Sep 2023CHF 52.6bCHF 9.8bCHF 1.5b35.4x35.3x5.4x
Tue, 15 Aug 2023CHF 53.2bCHF 9.8bCHF 1.5b35.5x34.4x5.4x
Thu, 13 Jul 2023CHF 55.6bCHF 9.7bCHF 1.6b37.2x34x5.7x
Sat, 10 Jun 2023CHF 58.7bCHF 9.7bCHF 1.6b37x35.9x6.1x
Price to Earnings Ratio

35.9x


Total Market Cap: CHF 58.7bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.3x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.62%
Healthcare-0.71%
Life Sciences1.26%
Clinical Research and Equipment1.26%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 496.401.0%
+CHF 342.2m		-12.0%PE38.1x
TECN Tecan GroupCHF 156.805.2%
+CHF 96.5m		-0.8%PS2.2x
SKAN SKAN GroupCHF 50.301.8%
+CHF 20.2m		-31.1%PE69.5x
PPGN PolyPeptide GroupCHF 38.300.1%
+CHF 1.7m		89.6%PS3.5x
XLS Xlife SciencesCHF 24.000.8%
+CHF 1.1m		20.9%PS497.1x

Latest News

BANB
CHF 71.00
Bachem Holding
7D
-10.9%
1Y
42.5%
LONN
CHF 496.40
Lonza Group
7D
1.0%
1Y
-12.0%
SFZN
CHF 78.35
Siegfried Holding
7D
-4.5%
1Y
-15.8%
Narrative Update • Jun 01

SFZN: Steady 2026 Guidance And Refined Views Will Support Future Upside

Analysts have modestly raised their average price target on Siegfried Holding by CHF 4 to reflect updated views on valuation, with one firm lifting its target by CHF 4 while another recently adjusted its target down to CHF 96, keeping expectations broadly in line with prior assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the share price, reflected in the CHF 4 upward adjustment.
TECN
CHF 156.80
Tecan Group
7D
5.2%
1Y
-0.8%
Narrative Update • May 31

TECN: Reduced P/E Expectations Will Limit Perceived Upside Potential

Analysts have trimmed their price targets on Tecan Group by CHF 1 to CHF 10 in recent updates. This reflects revised assumptions around discount rates, profit margins and future P/E expectations.
PPGN
CHF 38.30
PolyPeptide Group
7D
0.1%
1Y
89.6%
SKAN
CHF 50.30
SKAN Group
7D
1.8%
1Y
-31.1%
Narrative Update • May 15

SKAN: Order Backlog And Dividend Policy Will Support Future Returns

Analysts have kept their CHF 62.50 price target on SKAN Group unchanged, citing a slightly lower discount rate, more cautious assumptions on revenue growth and profit margins, and a higher future P/E multiple in their updated models. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026.
XLS
CHF 24.00
Xlife Sciences
7D
0.8%
1Y
20.9%